Propranolol is officially approved for sinus tachycardia, arrhythmias, obstructive cardiomyopathy, and angina pectoris, with likely widespread application in the United States.
Propranolol is officially approved for sinus tachycardia, arrhythmias, obstructive cardiomyopathy, and angina pectoris, with likely widespread application in the US.
IT is almost 10 years since the beta-adrenergic blocking drugs were reviewed in the pages of this journal.1 Although the clinical indications for the administration of propranolol have changed surprisingly little, it has taken some time for its use to become firmly established. It is now officially approved for use in sinus tachycardia, arrhythmias and obstructive cardiomyopathy and, more recently, in the treatment of angina pectoris. The addition of this last indication and the known antihypertensive effects of propranolol, which are at present under review, make it likely that the drug will enjoy more widespread application in the United States. . . .
David G. Shand (1975) conducted a review in Sinus tachycardia, arrhythmias, obstructive cardiomyopathy, and angina pectoris. Propranolol was evaluated. Propranolol is officially approved for sinus tachycardia, arrhythmias, obstructive cardiomyopathy, and angina pectoris, with likely widespread application in the United States.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: